Shopping Cart 0
Cart Subtotal
USD 0

Taiwan Liposome Company Ltd (4152) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Taiwan Liposome Company Ltd (TLC) is a clinical-stage pharmaceutical company that develops and commercializes novel nanomedicines based on drug delivery technology platform. The company's pipeline products include TLC599, TLC590, TLC399 and TLC178. Its TLC 178 is used for the treatment of adult advanced malignancies, soft tissue sarcoma and pediatric rhabdomyosarcoma. TLC holds expertise in lipid-based formulation and scale-up of parental drugs from nanoparticles for optimizing the pharmacokinetics of drugs. The company also develops BioSeizer lipid formulation technology and NanoX active drug loading technology. Its products find applications in the therapeutic areas of oncology, ophthalmology and oncology. The company has operations in Taiwan, the US, Japan and the Netherlands. TLC is headquartered in Taipei, Taiwan.

Taiwan Liposome Company Ltd (4152)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Taiwan Liposome Enters into Agreement with Sam Chun Dang Pharm 10

Taiwan Liposome Enters into Partnership Agreement with TTY Biopharm 11

Taiwan Liposome and Ablynx Enter into Research Agreement 12

Taiwan Liposome Enters Into Distribution Agreement With Sam Chun Dang Pharm For AmBiL 13

Taiwan Liposome Enters Into Co-Development Agreement With Yungshin Pharma 14

Licensing Agreements 15

Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 15

SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 16

Equity Offering 17

Taiwan Liposome Files Registration Statement for Public Offering of ADS for up to USD50 Million 17

Taiwan Liposome to Raise Funds through Private Placement of Shares 19

Taiwan Liposome Completes Public Offering Of Shares For USD 10 Million 20

Taiwan Liposome Completes Public Offering Of USD 100 Million 21

Acquisition 22

Jixi Agrosino to Acquire Minority Stake in TLC Biopharma from Taiwan Liposome for USD20 Million 22

Taiwan Liposome Company Ltd-Key Competitors 23

Taiwan Liposome Company Ltd-Key Employees 24

Taiwan Liposome Company Ltd-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Product News 26

10/16/2017: TLC Showcases Pain Drug Candidate TLC590 at Janney's Osteoarthritis & Pain Therapeutic Forum 26

10/11/2017: TLC to Present Update on Anesthetic Drug Candidate TLC590 at Janney's Osteoarthritis & Pain Therapeutic Forum 27

01/09/2017: Results of Phase 1/2 Clinical Trial of TLC599 in the Treatment of Osteoarthritis of the Knee 28

Product Approvals 29

Apr 03, 2018: TLC Announces Application with U.S. FDA for Proceeding of TLC590 as Investigational New Drug 29

Clinical Trials 30

Jul 25, 2017: TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399 30

Jul 11, 2017: TLC Announces Issuance of Patent for Dexamethasone Sodium Phosphate 31

Jan 03, 2017: TLC to Proceed with TLC599 Phase 2 Trial in Taiwan 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Taiwan Liposome Company Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Taiwan Liposome Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Taiwan Liposome Enters into Agreement with Sam Chun Dang Pharm 10

Taiwan Liposome Enters into Partnership Agreement with TTY Biopharm 11

Taiwan Liposome and Ablynx Enter into Research Agreement 12

Taiwan Liposome Enters Into Distribution Agreement With Sam Chun Dang Pharm For AmBiL 13

Taiwan Liposome Enters Into Co-Development Agreement With Yungshin Pharma 14

Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 15

SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 16

Taiwan Liposome Files Registration Statement for Public Offering of ADS for up to USD50 Million 17

Taiwan Liposome to Raise Funds through Private Placement of Shares 19

Taiwan Liposome Completes Public Offering Of Shares For USD 10 Million 20

Taiwan Liposome Completes Public Offering Of USD 100 Million 21

Jixi Agrosino to Acquire Minority Stake in TLC Biopharma from Taiwan Liposome for USD20 Million 22

Taiwan Liposome Company Ltd, Key Competitors 23

Taiwan Liposome Company Ltd, Key Employees 24

Taiwan Liposome Company Ltd, Other Locations 25

Taiwan Liposome Company Ltd, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Taiwan Liposome Company Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.